ArticleBiosensors2025
Detection of IgG Antibodies Against COVID-19 N-Protein by Hybrid Graphene-Nanorod Sensor.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic highlighted the global necessity to develop fast, affordable, and user-friendly diagnostic alternatives. Alongside recognized tests such as ELISA, nanotechnologies have since been explored for direct and indirect diagnosis of SARS-CoV-2, the etiological agent of COVID-19. Accordingly, in this work, we report a method to detect anti-SARS-CoV-2 antibodies based on graphene-based field-effect transistors (GFETs), using a nanostructured platform of graphene with added gold nanorods (GNRs) and a specific viral protein. To detect anti-N-protein IgG antibodies for COVID-19 in human sera, gold nanorods were functionalized with the nucleocapsid (N) protein of SARS-CoV-2, and subsequently deposited onto graphene devices. Our test results demonstrate that the sensor is highly sensitive and can detect antibody concentrations as low as 100 pg/mL. Using the sensor to test human sera that were previously diagnosed with ELISA showed a 90% accuracy rate compared to the ELISA results, with the test completed in under 15 min. Integrating graphene and nanorods eliminates the need for a blocker, simplifying sensor fabrication. This hybrid sensor holds robust potential to serve as a simple and efficient point-of-care platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.